Hypertension in Kidney Transplant Recipients : Where Are We Today?
PURPOSE OF REVIEW: Cardiovascular disease is the leading cause of death and allograft loss among kidney transplant recipients, and hypertension is an independent risk factor for cardiovascular morbidity of this patient population. The etiology of hypertension is multifactorial, including pre-transplant volume overload, post-transplant recipient and donor-associated variables, and transplant-specific causes (immunosuppressive medications, allograft dysfunction and surgical complications such as transplant artery stenosis).
RECENT FINDINGS: No randomized controlled trials have assessed the optimal blood pressure targets and explored the best antihypertensive regimen for kidney transplant recipients. According to the large observational studies, it is reasonable to achieve a blood pressure goal of equal to or less than 130/80 mmHg in the long-term follow-up for minimizing the cardiovascular morbidity. The selection of antihypertensive agents should be based on the patient's co-morbidities; however, the initial choice could be calcium channel blockers especially in the first few months of transplantation. In patients with cardiovascular indications of renin-angiotensin-aldosterone system inhibition, given the well-described benefits in diabetic and proteinuric patients, it is reasonable to consider the use of renin-angiotensin-aldosterone system inhibitors. There is a need for future prospective trials in the transplant population to define optimal blood pressure goals and therapies.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
Current hypertension reports - 23(2021), 4 vom: 13. Apr., Seite 21 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ari, Elif [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antihypertensive Agents |
---|
Anmerkungen: |
Date Completed 26.04.2021 Date Revised 05.05.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s11906-021-01139-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM324028059 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM324028059 | ||
003 | DE-627 | ||
005 | 20231225185438.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11906-021-01139-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1080.xml |
035 | |a (DE-627)NLM324028059 | ||
035 | |a (NLM)33847830 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ari, Elif |e verfasserin |4 aut | |
245 | 1 | 0 | |a Hypertension in Kidney Transplant Recipients |b Where Are We Today? |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.04.2021 | ||
500 | |a Date Revised 05.05.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a PURPOSE OF REVIEW: Cardiovascular disease is the leading cause of death and allograft loss among kidney transplant recipients, and hypertension is an independent risk factor for cardiovascular morbidity of this patient population. The etiology of hypertension is multifactorial, including pre-transplant volume overload, post-transplant recipient and donor-associated variables, and transplant-specific causes (immunosuppressive medications, allograft dysfunction and surgical complications such as transplant artery stenosis) | ||
520 | |a RECENT FINDINGS: No randomized controlled trials have assessed the optimal blood pressure targets and explored the best antihypertensive regimen for kidney transplant recipients. According to the large observational studies, it is reasonable to achieve a blood pressure goal of equal to or less than 130/80 mmHg in the long-term follow-up for minimizing the cardiovascular morbidity. The selection of antihypertensive agents should be based on the patient's co-morbidities; however, the initial choice could be calcium channel blockers especially in the first few months of transplantation. In patients with cardiovascular indications of renin-angiotensin-aldosterone system inhibition, given the well-described benefits in diabetic and proteinuric patients, it is reasonable to consider the use of renin-angiotensin-aldosterone system inhibitors. There is a need for future prospective trials in the transplant population to define optimal blood pressure goals and therapies | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Antihypertensive treatment | |
650 | 4 | |a Calcium channel blocker | |
650 | 4 | |a Hypertension | |
650 | 4 | |a Kidney transplantation | |
650 | 4 | |a Renin-angiotensin system | |
650 | 7 | |a Antihypertensive Agents |2 NLM | |
700 | 1 | |a Fici, Francesco |e verfasserin |4 aut | |
700 | 1 | |a Robles, Nicolas Roberto |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current hypertension reports |d 1999 |g 23(2021), 4 vom: 13. Apr., Seite 21 |w (DE-627)NLM109021290 |x 1534-3111 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2021 |g number:4 |g day:13 |g month:04 |g pages:21 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11906-021-01139-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2021 |e 4 |b 13 |c 04 |h 21 |